Video

Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLC

Author(s):

Leora Horn, MD

In Partnership With:

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses the FDA approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses the FDA approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non—small cell lung cancer (NSCLC).

Related Videos
Arndt Vogel, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Ben Levy, MD, and Yan Leyfman, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
Related Content
Taletrectinib in ROS1-positive non–small cell lung cancer: © stock.adobe.com
June 2nd 2024

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

David R. Spigel, MD, of Sarah Cannon Research Institute
June 2nd 2024

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation

Carrie L. Kitko, MD, associate professor, pediatrics, medical director, the Pediatric Stem Cell Transplantation Program, the Ingram Professor of Pediatric Oncology, Monroe Carell Jr. Children’s Hospital at Vanderbilt; Sagar S. Patel, MD, director, Communications and Media Relationships, the Division of Hematology, the University of Utah Huntsman Cancer Institute
February 19th 2024

Kitko and Patel Emphasize the Importance of GVHD Research and Awareness

Tony S. K. Mok, MD
June 1st 2024

Adagrasib Improves Survival, Responses in KRAS G12C+ Advanced NSCLC

Natasha B. Leighl, BSc, MMSc, MD
June 1st 2024

Subcutaneous Amivantamab Shows Noninferior ORR vs IV Formulation in EGFR+ NSCLC